Page 14 - PRESENTATION

OS and PFS benefit with avelumab 1L maintenance occurred

irrespective of 1L chemotherapy regimen

Gemcitabine + carboplatin (N=269)

Median OS (95% CI), months Median PFS (95% CI), months

100 Avelumab + BSC 19.9 (16.0, 24.0) 100 Avelumab + BSC 3.0 (2.0, 3.7)
BSC alone 12.9 (9.4, 16.2) BSC alone 1.9 (1.9, 2.0)
90 90
HR 0.66 (95% CI, 0.47, 0.91) HR 0.59 (95% CI, 0.44, 0.80)
80 80
70 70
60 60
OS, % 50 PFS, % 50

40 40
30 30
20 20
10 10
0 0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38
Months Months
No. at risk No. at risk
Avelumab +BSC 147 142 130 119 102 88 78 68 59 48 32 21 16 14 9 6 5 1 1 0 Avelumab +BSC 147 72 48 41 33 25 20 18 16 9 7 6 3 1 0
BSC 122 114 104 91 72 57 52 42 36 29 20 15 13 12 6 3 3 0 BSC 122 42 22 8 7 5 5 4 3 3 1 1 1 0

•OS and PFS were measured post randomization (after chemotherapy) Grivas P, ESMO 2020